Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by ronrydellon Mar 01, 2013 7:34pm

264 Views

Post# 21065312

RE: RE: end of month

Next week could be interesting..be great to have a daily consistent climb up to $3.00, than past for a next Friday close at $3.25. interesting how the pullbacks kept coming back for a nice close at $2.65. I think that this time we're on our way for a great March and April. Time to buy now before the institutions get in at $5.00 and makes volume purchases prohibitive.

Bullboard Posts

Changing Europe’s dependency on HREE from China